



Date: November 11, 2024

To
The Manager,
Listing Department,
National Stock Exchange of India Ltd.,
Exchange Plaza, Plot No. C-1, Block G,
Bandra Kurla Complex, Bandra (E), Mumbai - 400 051.

NSE SYMBOL: UNIHEALTH

Dear Sir/ Madam,

Sub: Outcome of the Board Meeting - November 11, 2024

Ref: Intimation under Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations").

Pursuant to Regulation 30 and 33 of SEBI Listing Regulations, this is to inform that the Board of Directors at its meeting held on Monday, November 11, 2024, inter-alia, considered and approved the Unaudited Standalone and Consolidated Financial Results for the half year ended September 30, 2024, together with the Limited Review Report of the Auditor's thereon, Statement of Assets and Liabilities and Cashflow statement as at September 30, 2024 which are enclosed herewith;

Further, please find enclosed the following:

1. Statement of Deviation or Variation as required under Regulation 32(1) of the SEBI Listing Regulations;
2. Certificate indicating utilisation of issue proceeds pursuant to NSE circular No: NSE/CML/2024/23 dated September 05, 2024.

The trading window for dealing in securities of the Company shall open on Thursday, November 14, 2024, being 48 hours after declaration of Financial Results by the Company for the half year ended September 30, 2024.

The Meeting commenced at 01.00 P.M. and concluded at 01.55 P.M.
Kindly take the above on your records.

Thanking you.
Yours faithfully,

For Unihealth Consultancy Limited
(Formerly Unihealth Consultancy Private Limited)

Binita
Mayur Patel

Binita Patel

Company Secretary / Compliance Officer

Encl.: As above



UniHealth Consultancy Limited

(Formerly known as Unihealth Consultancy Private Limited)

Registered Office : H-13/14, Everest, 156, Tardeo Road, Mumbai - 400 034, Maharashtra, India.

+91 22 2354 4625 / 27 info@unihealthonline.com www.unihealthonline.com | www.umchospitals.com

CIN No.: L85100MH2010PLC200491

UNIHEALTH CONSULTANCY LIMITED
(Formerly known as UNIHEALTH CONSULTANCY PRIVATE LIMITED)
H-13/14 Everest, 156, Tardeo Road, Mumbai, Maharashtra 400034
CIN : L85100MH2010PLC200491

STANDALONE STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE HALF YEAR ENDED 30TH SEPTEMBER, 2024

		(Rs. In lakhs)			
	PARTICULARS	For the Half Year Ended 30.09.2024	For the Half Year Ended 31.03.2024	For the Half Year Ended 30.09.2023	For the Year Ended 31.03.2024
		Unaudited	Audited	Unaudited	Audited
I	Revenue from operations	155.88	331.01	91.91	422.92
II	Other income	150.35	136.71	95.92	232.63
III	Total revenue (I + II)	306.23	467.72	187.83	655.55
IV	Expenses				
-	Cost of materials consumed	-	-	-	-
-	Purchases of stock in trade	-	-	-	-
-	Changes in inventories of Finished goods, Work in progress and Stock-in- trade	-	-	-	-
-	Employee benefits expense	79.84	67.35	59.02	126.37
-	Finance costs	0.02	1.63	31.87	33.50
-	Depreciation and amortization expense	13.37	11.76	3.81	15.57
-	Other expenses	58.24	37.12	64.42	101.54
V	Total Expense (IV)	151.47	117.86	159.12	276.98
VI	Profit/(Loss) before exceptional and extra-ordinary items and Tax (III - V)	154.76	349.86	28.71	378.57
VII	Exceptional Items	-	-	-	-
VIII	Profit/(Loss) before extra-ordinary items and Tax	154.76	349.86	28.71	378.57
IX	Extra-Ordinary Items	-	-	-	-
X	Profit/(Loss) Before Tax (VIII-IX)	154.76	349.86	28.71	378.57
XI	Tax expense				
(1)	Current tax	41.02	54.21	-	54.21
(2)	Deferred tax	0.99	41.76	(20.90)	20.86
XII	Total Tax Expense	42.01	95.97	(20.90)	75.07
XIII	Profit/(Loss) for the period from continuing operations (X-XII)	112.75	253.89	49.61	303.50
	Profit/(Loss) from discontinuing operations before tax	-	-	-	-
	Tax expense of discontinuing operations	-	-	-	-
XIII	Profit/(Loss) from discontinuing operations after tax	-	-	-	-
XIV	Profit/(Loss) for period before minority interest	112.75	253.89	49.61	303.50
	Share of profit/(loss) of associates	-	-	-	-
	Profit/Loss of minority interest	-	-	-	-
XV	Net Profit/(Loss) for the period	112.75	253.89	49.61	303.50
XVI	Details of Equity Share Capital				
	Paid-up Equity Share Capital	1,540.00	1,540.00	1,540.00	1,540.00
	Rs 10/-		Rs 10/-		Rs 10/-
	Face Value of equity share capital				
	Reserves excluding revaluation reserve	5,020.10	4,907.34	4,665.56	4,907.34
XI	Earnings per equity share:				
(a)	Basic EPS from continuing and discontinued operations	0.73	1.65	0.43	2.26
(b)	Diluted EPS from continuing and discontinued operations	0.73	1.65	0.43	2.26
XII	Debt Equity Ratio	0.02	0.05	0.10	0.05
XIII	Debt Service Coverage Ratio	0.78	0.08	0.06	0.08
XIV	Interest Service Coverage Ratio	9,335.99	215.64	1.90	12.30




NOTES:

- 1 As per MCA Notification dated 16th February 2015, companies whose shares are listed on SME exchange as referred to in Chapter XB of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2009 are exempted from the compulsory requirement of adoption of IND AS. As the Company is covered under the exempted category, it has not adopted IND AS for the preparation of financial results.
- 2 The Statutory Auditor of the Company has carried out review of the financial results for the Half Year ended on September 30, 2024 in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The above financial results have been reviewed and recommended by the Audit Committee and subsequently approved by the Board of Directors at its meeting held 11th November, 2024.
- 3 Figures for the previous periods /year have been regrouped, restated and /or reclassified wherever considered necessary to make them comparable to the current periods /presentation.
- 4 The aforesaid results have been filed with Stock Exchanges under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are also available on the Stock Exchanges websites and on the website of the Company.
- 5 The Company is not a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P /2018/144 dated 26th November, 2018.
- 6 There are no investors complaints pending as on 30th September, 2024.
- 7 The figures for half year ended 31st March, 2024 are the balancing figures between the audited figures in respect of Financial Year 2023-24 and the published unaudited figures of the Half Year ended September 30, 2023, which were subject to limited review.
- 8 UMC Global Health Ltd (Nigeria), which was previously a joint venture, has now been converted into a subsidiary company by virtue of acquisition of additional shares through right issue allotted on 30th September, 2024.
- 9 Pursuant to a resolution passed by Board of Directors of the company on 06th May 2024, the Company has approved to become first subscriber of Memorandum of Association of UMC Hospitals Private Limited by subscribing for 1,52,000 no. of equity shares (80% of shareholding, making it a Subsidiary of the Company) on 22nd May, 2024, amounting to Rs.15,20,000. Payment for the said subscription was effected on 05th July, 2024.
- 10 The name of the company has been changed from Unihealth Consultancy Limited to Unihealth Hospitals Limited vide MCA certificate of Incorporation dated 14th October, 2024. The name change application made to NSE is in process.
- 11 A wholly owned subsidiary company namely "Unihealth Holding Limited" of the company was incorporated in Mauritius on 7th May, 2024.
- 12 EPS for half year ended 31st March 2024 and 30th September 2023 is not annualised and arrived at after considering IPO equity shares (42,84,000) issued on 15th September, 2023.
- 13 The proceeds from the Equity shares IPO issued was amounting to Rs 5654.88 lakhs. The object and proposed utilization of IPO Proceeds and amount utilized as on September 30, 2024 is as under:-

Object	(amount in Lakhs)	
	Proposed Utilization	Amount Utilized
Investment in our joint venture, Victoria Hospital Limited (VHL), Kampala, Uganda for funding its capital expenditure requirements for proposed expansion and working capital requirements of VHL	1700.00	1259.02
Investment in our joint venture, UMC Global Health Limited (UMCGHL), Nigeria for funding its capital expenditure requirements for proposed expansion	460.00	111.56
Investment in our subsidiary, Biohealth Limited (BL), Tanzania for funding its capital expenditure requirements for proposed expansion*	237.50	169.60
Investment in our subsidiaries UMC Hospitals Private Limited (India) and in Unihealth Holdings Limited (Mauritius) to support expansion and acquisition of projects across India and Africa*	1350.00	439.05
General Corporate Purpose	1093.08	1093.08
Issue Expenses	814.30	814.30

* The original object as disclosed in the offer document was further altered by passing a resolution to vary the utilisation of proceeds raised by the Company through an initial public offering of equity shares (the 'IPO') made in pursuance of the Prospectus dated September 14, 2023 (the 'Prospectus') and reallocate the unutilized proceeds for the objects as set out in the Postal Ballot Notice, have been passed with requisite majority on Wednesday, June 26, 2024. Out of initial proposed amount i.e. Rs. 1587.50 Lakhs, Rs.1350 Lakhs were reallocated for investing as equity and debt in UMC Hospitals Private Limited, a subsidiary of the Company in India and in Unihealth Holdings Limited, the wholly owned subsidiary of the Company in Mauritius, to support expansion and acquisition of projects across India and Africa, in furtherance of the current objects of the Company.

For and on behalf of Board of
Unihealth Consultancy Limited
(Formerly known as Unihealth Consultancy Private Limited)


Akshay M Parmar
Managing Director
DIN:01533004
Place : Mumbai
Date: 11/11/2024



UNIHEALTH CONSULTANCY LIMITED
(Formerly known as UNIHEALTH CONSULTANCY PRIVATE LIMITED)
H-13/14 Everest, 156, Tardeo Road, Mumbai, Maharashtra 400034
CIN : L85100MH2010PLC200491

UNAUDITED STANDALONE STATEMENT OF ASSETS AND LIABILITIES AS AT 30TH SEPTEMBER, 2024

Particulars	(Rs. In lakhs)	
	As at 30th September 2024	As at 31st March 2024
	Unaudited	Audited
I. EQUITY AND LIABILITIES		
(1) Shareholder's Funds		
(a) Share Capital	1,540.00	1,540.00
(b) Reserve & Surplus	5,020.10	4,907.34
(c) Money received against share warrants	-	-
	6,560.10	6,447.34
(2) Share Application Money Pending Allotment		
(3) Non-Current Liabilities		
(a) Long-term borrowings	115.00	329.97
(b) Deferred tax liabilities (Net)	-	-
(c) Other Long term liabilities	-	-
(d) Long term provisions	29.33	25.85
	144.33	355.82
(4) Current Liabilities		
(a) Short-term borrowings	-	-
(b) Trade payables	-	-
(i) Total outstanding dues of micro enterprises and small enterprises	-	0.28
(ii) Total outstanding dues of creditors other than micro enterprises and small enterprises	0.98	2.55
(c) Other current liabilities	31.88	26.36
(d) Short-term provisions	42.92	15.58
	75.78	44.77
Total	6,780.21	6,847.93
II. ASSETS		
(1) Non-current assets		
(a) Property, Plant and Equipment and Intangible Asset		
(i) Property, Plant and Equipment	315.85	306.62
(ii) Intangible assets	4.68	2.14
(iii) Capital work-in-progress	-	-
(iv) Intangible assets under development	-	-
(b) Non-current investments	2,304.93	1,837.36
(c) Deferred tax assets (net)	0.47	1.46
(d) Long term loans and advances	1,642.63	1,367.64
(e) Other non-current assets	119.51	204.99
	4,388.07	3,720.21
(2) Current assets		
(a) Current Investments	-	-
(b) Inventories	-	-
(c) Trade receivables	319.39	260.78
(d) Cash and cash equivalents	1,782.68	2,664.28
(e) Short-term loans and advances	6.55	3.67
(f) Other current assets	283.52	198.99
	2,392.14	3,127.72
Total	6,780.21	6,847.93

For and on behalf of Board of
Unihealth Consultancy Limited
(Formerly known as Unihealth Consultancy Private Limited)


Akshay M Parmar
Managing Director
DIN:01533004
Place : Mumbai
Date: 11/11/2024




UNIHEALTH CONSULTANCY LIMITED
(Formerly known as UNIHEALTH CONSULTANCY PRIVATE LIMITED)
H-13/14 Everest, 156, Tardeo Road, Mumbai, Maharashtra 400034
CIN : L85100MH2010PLC200491
UNAUDITED STANDALONE STATEMENT OF CASH FLOW FOR THE HALF YEAR ENDED 30TH SEPTEMBER, 2024

(Rs. In lakhs)		
Particulars	As at 30 September, 2024	For the year ended, 31st March 2024
	Unaudited	Audited
A Cash flow from operating activities		
Net profit before tax	154.76	378.57
Adjustments for:		
Depreciation/amortization	13.37	15.57
Short/Excess Provision for Tax	-	(0.20)
Finance Cost	0.02	33.50
Foreign exchange (gain)/Loss	4.94	8.66
Miscellaneous Income	-	-
Interest on refunds from income tax	-	-
Interest on FD	(56.12)	(52.31)
Interest on Loan given	(86.73)	(166.10)
Operating profit before working capital changes	30.24	217.69
Changes in assets and liabilities:		
(Increase) / decrease in Trade Receivables	(58.61)	(198.34)
(Increase) / decrease in Short term Loans and Advances	(2.88)	31.01
Increase / (decrease) in Current Liabilities	5.52	(12.46)
Increase / (decrease) in Short term Provisions	0.08	12.12
Increase / (decrease) in Long term Provisions	3.48	10.76
Increase / (decrease) in Trade Payables	(1.84)	(0.23)
(Increase) / decrease in Other Non Current Assets	164.75	(113.83)
(Increase) / decrease in Other Current Assets	82.42	(138.81)
Cash (used in)/ generated from operating activities	223.16	(192.09)
Income tax paid	(33.51)	(54.21)
Net cash from/ (used in) from operating activities (A)	189.65	(246.30)
B Cash flow from Investing activities		
(Increase) / decrease in Long term Loans & Advances	(501.46)	116.96
Interest on Loan Given	86.73	166.10
Interest on Fixed Deposit	56.12	52.31
Purchase of Permanent Investments	(467.57)	(1,203.49)
Purchase of fixed assets	(25.14)	(182.16)
Net cash from/ (used in) from investing activities (B)	(851.32)	(1,050.28)
C Cash flow from Financing activities		
Proceeds from Issuance of Share Capital	-	5,654.88
Share Issue Expenses	-	(777.70)
Proceeds/ (Repayment) of Borrowings	(214.97)	(877.81)
Foreign exchange (gain)/Loss	(4.94)	(8.66)
Miscellaneous Income	-	-
Finance cost	(0.02)	(33.50)
Net cash from / (used in) from financing activities (C)	(219.93)	3,957.21
Net increase / (decrease) in cash and cash equivalents (A+B+C)	(881.60)	2,660.63
Cash and cash equivalents at the beginning of the period	2,664.28	3.65
Cash and cash equivalents at the end of the period	1,782.68	2,664.28

Notes:

- The cash flow statement has been prepared in accordance with the requirements of Accounting standard - 3 - Cash flow Statement issued in terms of section 133 of the Companies Act, 2013.

For and on behalf of Board of
Unihealth Consultancy Limited
(Formerly known as Unihealth Consultancy Private Limited)


Akshay M Parmar
Managing Director
DIN:01533004
Place : Mumbai
Date: 11/11/2024



UNIHEALTH CONSULTANCY LIMITED
(Formerly known as UNIHEALTH CONSULTANCY PRIVATE LIMITED)
H-13/14 Everest, 156, Tardeo Road, Mumbai, Maharashtra 400034
CIN : L85100MH2010PLC200491

CONSOLIDATED STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE HALF YEAR ENDED 30TH SEPTEMBER, 2024

		(Rs. In lakhs)			
	PARTICULARS	For the Half Year Ended 30.09.2024	For the Half Year Ended 31.03.2024	For the Half Year Ended 30.09.2023	For the Year Ended 31.03.2024
		Unaudited	Audited	Unaudited	Audited
I	Revenue from operations	2,382.53	2,664.62	2,210.38	4,875.00
II	Other income	143.41	85.36	74.91	160.27
III	Total revenue (I + II)	2,525.94	2,749.98	2,285.29	5,035.27
IV	Expenses				
-	Cost of materials consumed	-	-	-	-
-	Purchases of stock in trade	492.57	451.99	484.02	936.01
-	Changes in inventories of Finished goods, Work in progress and Stock-in-trade	18.25	(56.62)	(13.83)	(70.45)
-	Employee benefits expense	392.83	371.81	360.72	732.53
-	Finance costs	102.54	172.50	153.49	325.99
-	Depreciation and amortization expense	114.17	112.16	114.16	226.32
-	Other expenses	681.54	850.78	669.92	1,520.70
V	Total Expense (IV)	1,801.90	1,902.62	1,768.48	3,671.10
VI	Profit/(Loss) before exceptional and extra-ordinary items and Tax (III - V)	724.04	847.36	516.81	1,364.17
VII	Exceptional Items	-	-	-	-
VIII	Profit/(Loss) before extra-ordinary items and Tax	724.04	847.36	516.81	1,364.17
IX	Extra-Ordinary Items	-	-	-	-
X	Profit/(Loss) Before Tax (VIII-IX)	724.04	847.36	516.81	1,364.17
XI	Tax expense				
	(1) Current tax	196.84	147.81	105.54	253.35
	(2) Deferred tax	9.82	90.77	(18.48)	72.29
XII	Total Tax Expense	206.66	238.58	87.06	325.64
XIII	Profit/(Loss) for the period from continuing operations (X-XII)	517.38	608.78	429.75	1,038.53
	Profit/(Loss) from discontinuing operations before tax	-	-	-	-
	Tax expense of discontinuing operations	-	-	-	-
XIII	Profit/(Loss) from discontinuing operations after tax	-	-	-	-
XIV	Profit/(Loss) for period before minority interest	517.38	608.78	429.75	1,038.53
	Add: Share of profit/(loss) of associates	3.86	(3.75)	(4.39)	(8.14)
	Less: Profit/(Loss) of minority interest	(1.47)	(1.31)	1.04	(0.27)
XV	Net Profit/(Loss) for the period	522.71	606.34	424.32	1,030.66
XVI	Details of Equity Share Capital				
	Paid-up Equity Share Capital	1,540.00	1,540.00	1,540.00	1,540.00
	Face Value of equity share capital	Rs 10/-	Rs 10/-	Rs 10/-	Rs 10/-
	Reserves excluding revaluation reserve	7,658.64	7,004.94	6,520.32	7,004.94
XI	Earnings per equity share:				
	(a) Basic EPS from continuing and discontinued operations	3.39	3.94	3.69	7.67
	(b) Diluted EPS from continuing and discontinued operations	3.39	3.94	3.69	7.67
XII	Debt Equity Ratio	0.11	0.36	0.36	0.18
XIII	Debt Service Coverage Ratio	0.87	0.17	0.39	0.22
XIV	Interest Service Coverage Ratio	8.06	5.91	4.37	5.18



NOTES :

- 1 As per MCA Notification dated 16th February 2015, companies whose shares are listed on SME exchange as referred to in Chapter XB of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2009 are exempted from the compulsory requirement of adoption of IND AS. As the Company is covered under the exempted category, it has not adopted IND AS for the preparation of financial results.
- 2 The Statutory Auditors of the Company have carried out review of the financial results for the Half Year ended on September 30, 2024 in compliance with terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The above financial results have been reviewed and recommended by the Audit Committee and subsequently approved by the Board of Directors at its meeting held 11th November, 2024.
- 3 Figures for the previous periods /year have been regrouped ,restated and /or reclassified wherever considered necessary to make them comparable to the current periods /presentation.
- 4 The aforesaid results have been filed with Stock Exchanges under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are also available on the Stock Exchanges websites and on the website of the Company.
- 5 The Company is not a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P /2018/144 dated 26th November, 2018.
- 6 There are no investors complaints pending as on 30th September , 2024.
- 7 The figures for half year ended 31st March, 2024 are the balancing figures between the audited figures in respect of Financial Year 2023-24 and the published unaudited figures of the Half Year ended September 30, 2023, which were subject to limited review.
- 8 UMC Global Health Ltd (Nigeria), which was previously a joint venture, has now been converted into a subsidiary company by virtue of acquisition of additional shares through right issue allotted on 30th September 2024. Hence, The same has been considered as a joint venture for the above published results.
- 9 Pursuant to a resolution passed by Board of Directors of the company on 06th May 2024, the Company has approved to become first subscriber of Memorandum of Association of UMC Hospitals Private Limited by subscribing for 1,52,000 no. of equity shares (80% of shareholding, making it a Subsidiary of the Company) on 22nd May, 2024, amounting to Rs.15,20,000. Payment for the said subscription was effected on 05th July, 2024.
- 10 The name of the company has been changed from Unihealth Consultancy Limited to Unihealth Hospitals Limited vide MCA certificate of Incorporation dated 14th October, 2024. The name change application made to NSE is in process.
- 11 A wholly owned subsidiary company namely "Unihealth Holding Limited" of the company was incorporated in Mauritius on 07th May, 2024.
- 12 EPS for half year ended 31st March 2024 and 30th September 2023 is not annualised and arrived at after considering IPO equity shares (42,84,000) issued on 15th September 2023.
- 13 The proceeds from the Equity shares IPO issued was amounting to Rs 5654.88 lakhs. The object and proposed utilization of IPO Proceeds and amount utilized as on September 30, 2024 is as under:-

Object	(amount in Lakhs)	
	Proposed Utilization	Amount Utilized
Investment in our joint venture, Victoria Hospital Limited (VHL), Kampala, Uganda for funding its capital expenditure requirements for proposed expansion and working capital requirements of VHL	1700.00	1259.02
Investment in our joint venture, UMC Global Health Limited (UMCGHL), Nigeria for funding its capital expenditure requirements for proposed expansion	460.00	111.56
Investment in our subsidiary, Biohealth Limited (BL), Tanzania for funding its capital expenditure requirements for proposed expansion*	237.50	169.60
Investment in our subsidiaries UMC Hospitals Private Limited (India) and in Unihealth Holdings Limited (Mauritius) to support expansion and acquisition of projects across India and Africa*	1350.00	439.05
General Corporate Purpose	1093.08	1093.08
Issue Expenses	814.30	814.30

* The original object as disclosed in the offer document was further altered by passing a resolution to vary the utilisation of proceeds raised by the Company through an initial public offering of equity shares (the 'IPO') made in pursuance of the Prospectus dated September 14, 2023 (the 'Prospectus') and reallocate the unutilized proceeds for the objects as set out in the Postal Ballot Notice, have been passed with requisite majority on Wednesday, June 26, 2024. Out of initial proposed amount i.e. Rs. 1587.50 Lakhs, Rs.1350 Lakhs were reallocated for investing as equity and debt in UMC Hospitals Private Limited, a subsidiary of the Company in India and in Unihealth Holdings Limited, the wholly owned subsidiary of the Company in Mauritius, to support expansion and acquisition of projects across India and Africa, in furtherance of the current objects of the Company.

For and on behalf of Board of
Unihealth Consultancy Limited
(Formerly known as Unihealth Consultancy Private Limited)


Akshay M Parmar
Managing Director
DIN:01533004
Place : Mumbai
Date: 11/11/2024




UNIHEALTH CONSULTANCY LIMITED
(Formerly known as UNIHEALTH CONSULTANCY PRIVATE LIMITED)
H-13/14 Everest, 156, Tardeo Road, Mumbai, Maharashtra 400034
CIN : L85100MH2010PLC200491

UNAUDITED CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES AS AT 30TH SEPTEMBER, 2024

Particulars	(Rs. In lakhs)	
	As at 30th September 2024	As at 31st March 2024
	Unaudited	Audited
I. EQUITY AND LIABILITIES		
(1) Shareholder's Funds		
(a) Share Capital	1,540.00	1,540.00
(b) Reserve & Surplus	7,658.64	7,004.94
(c) Money received against share warrants		
	9,198.64	8,544.94
(d) Minority Interest	(26.03)	(24.55)
(2) Share Application Money Pending Allotment	-	-
(3) Non-Current Liabilities		
(a) Long-term borrowings	704.50	1,175.81
(b) Deferred tax liabilities (Net)	176.25	157.03
(c) Other Long term liabilities	-	-
(d) Long term provisions	29.33	25.85
	910.08	1,358.69
(4) Current Liabilities		
(a) Short-term borrowings	323.73	339.97
(b) Trade payables		
(i) Total outstanding dues of micro enterprises and small enterprises	-	0.28
(ii) Total outstanding dues of creditors other than micro enterprises and small enterprises	264.71	246.54
(c) Other current liabilities	473.86	365.49
(d) Short-term provisions	192.35	189.31
	1,254.65	1,141.59
Total	11,337.34	11,020.67
II. ASSETS		
(1) Non-current assets		
(a) Property, Plant and Equipment and Intangible Asset		
(i) Property, Plant and Equipment	2,981.80	2,809.99
(ii) Intangible assets	11.28	10.02
(iii) Goodwill on consolidation	751.46	751.46
(iv) Capital work-in-progress	69.23	37.48
(v) Intangible assets under development	-	-
(b) Non-current investments	24.76	20.90
(c) Deferred tax assets (net)	-	-
(d) Long term loans and advances	699.71	528.88
(e) Other non-current assets	129.62	164.31
	4,667.86	4,323.04
(2) Current assets		
(a) Current Investments	-	-
(b) Inventories	195.93	208.31
(c) Trade receivables	3,730.03	3,356.76
(d) Cash and cash equivalents	2,430.91	2,850.84
(e) Short-term loans and advances	69.34	59.07
(f) Other current assets	243.27	222.65
	6,669.48	6,697.63
Total	11,337.34	11,020.67

For and on behalf of Board of
Unihealth Consultancy Limited
(Formerly known as Unihealth Consultancy Private Limited)


Akshay M Parmar
Managing Director
DIN:01533004
Place : Mumbai
Date: 11/11/2024



UNIHEALTH CONSULTANCY LIMITED
(Formerly known as UNIHEALTH CONSULTANCY PRIVATE LIMITED)
H-13/14 Everest, 156, Tardeo Road, Mumbai, Maharashtra 400034
CIN : L85100MH2010PLC200491


UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOW FOR THE HALF YEAR ENDED 30TH SEPTEMBER, 2024

		(Rs. In lakhs)	
Particulars		For the half year ended 30th September, 2024	For the year ended 31st March, 2024
		Unaudited	Audited
A Cash flow from operating activities			
Net profit before tax		724.04	1,364.17
Adjustments for:			
Depreciation/amortization		114.17	226.32
(Short)/Excess Provision for tax		-	(0.20)
(Profit)/Loss on sale of Fixed Asset		(1.01)	-
Balances Written (Back)/Off		(3.23)	(1.57)
Finance Cost		102.54	325.99
Rent Receipts		(1.08)	(2.16)
Int on Income tax refund		-	-
Foregin Exchange (Gain)/Loss		(41.88)	(15.40)
Insurance Claim Received		-	(0.03)
Interest on FD & Loan given		(95.35)	(137.91)
Operating profit before working capital changes		798.20	1,759.21
Changes in assets and liabilities:			
(Increase) / decrease in Inventories		12.38	2.92
(Increase) / decrease in Trade Receivables		(373.27)	(617.40)
(Increase) / decrease in Short Term Loans and Advances		(10.27)	44.06
(Increase) / decrease in Current and Non Current Assets		14.07	(216.80)
Increase / (decrease) in Current and Non Current Laibilities		108.37	(203.21)
Increase / (decrease) in Long term and Short term Provisions		5.50	(11.75)
Increase / (decrease) in Trade Payables		21.13	(47.61)
Cash (used in)/ generated from operating activities		576.11	709.42
Income tax		(216.06)	(253.35)
Net cash from/ (used in) from operating activities (A)		360.05	456.07
B Cash flow from Investing activities			
(Increase) / decrease in long term loans & advances		(170.82)	(148.52)
Interest on FD & Loan given		95.35	137.91
Sale of Fixed Asset		-	5.03
Rent Receipts		1.08	2.16
Investment in associate		-	0.33
Loss/(Profit) on sale of assets		-	-
Purchase of fixed assets		(318.99)	(238.00)
Net cash from/ (used in) from investing activities (B)		(393.38)	(241.09)
C Cash flow from Financing activities			
Proceeds/(Repayment) of Borrowings		(487.57)	(2,410.89)
Foreign Exchange Gain/(Loss)		41.88	15.40
Proceeds from Issuance of Share Capital		-	5,654.88
Share Issue Expenses		-	(777.70)
Finance cost		(102.54)	(325.99)
Net cash from / (used in) from financing activities (C)		(548.23)	2,155.70
Net increase / (decrease) in cash and cash equivalents (A+B+C)		(581.56)	2,370.68
Cash and cash equivalents at the beginning of the period		2,850.84	195.38
Effect of Foreign Exchange Gain or Loss		161.63	284.78
Cash and cash equivalents at the end of the period		2,430.91	2,850.84

Notes:

- The cash flow statement has been prepared in accordance with the requirements of Accounting standard - 3 - Cash flow Statement issued in terms of section 133 of the Companies Act, 2013.

For and on behalf of Board of
Unihealth Consultancy Limited
(Formerly known as Unihealth Consultancy Private Limited)


Akshay M Parmar
Managing Director
DIN:01533004
Place : Mumbai
Date: 11/11/2024



Limited Review Report on unaudited financial results and year to date results of Unihealth Consultancy Limited under regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015

To,
Board of Directors,
Unihealth Consultancy Limited

We have reviewed the accompanying statement of unaudited financial results of **Unihealth Consultancy Limited** (herein after referred as 'the Company') for the Half Year ended 30th September 2024. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For G.P Kapadia & Co.
(Chartered Accountants)
FRN No.: 104768W

Digitally signed by ATUL

BABUBHAI DESAI

Date: 2024.11.11 13:40:00 +05'30'

Atul Desai

(Partner)

Membership No. 030850

Place: Mumbai

Date: 11th November 2024

UDIN: 24030850BKAWGM3708

G. P. KAPADIA & CO.

Chartered Accountants

4th Floor, Hamam House, Ambalal Doshi Marg, Fort, Mumbai - 400 001

+ 91 22 2265 4239 / 4313 info.ho@gpkapadia.com www.gpkapadia.com



Limited Review Report on the Consolidated unaudited Financial Results of Unihealth Consultancy Limited for the half year ended September 30, 2024 pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 (as amended).

To,
The Board of Directors
Unihealth Consultancy Limited

1. We have reviewed the accompanying statement of consolidated unaudited financial results of **Unihealth Consultancy Limited** (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") its associates and joint ventures for the half year ended September 30, 2024 ("the Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (the "Listing Regulation, 2015"). The Statement is the responsibility of the Holding Company's management and has been approved by the board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard 25 "Interim Financial Reporting" (AS 25), prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard. requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedure applied financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities :

Sr. No.	Name	Relationship
1	Unihealth Pharmaceuticals Private Limited	Subsidiary
2	Aryavarta FZE	Subsidiary
3	Unihealth Tanzania Limited	Subsidiary
4	Biohealth Limited	Subsidiary
5	UMC Global Health Limited	Joint venture
6	UMC Hospitals Private Limited	Subsidiary
7	Unihealth Holdings Limited	Subsidiary
8	Victoria Hospital Limited	Joint venture
9	UHS Oncology Private Limited	Associate
10	Unihealth Uganda Limited	Associate

5. Based on our review conducted and procedures performed as stated in paragraph 2 above, nothing has come to our attention that causes us to believe that the Statement has been prepared in all material respects in accordance with the applicable Accounting Standards prescribed under section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014 and other recognized accounting practices and policies, and has disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 (as amended) including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial results of subsidiaries and Joint Ventures included in the consolidated unaudited financial results, whose interim financial results reflect audited total assets of Rs 5759.52 lakhs and cash flows of Rs (0.30) lakhs as at 30th September 2024, audited total revenue from operations of Rs 2226.49 lakhs for the period ended 30 September 2024, as considered in the consolidated unaudited financial results. These financial results have been audited by other auditors and our opinion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of this Subsidiary companies and Joint Ventures is based solely on the financial result of the those subsidiaries and joint ventures as referred aforesaid. Our conclusion on the Statement is not modified in respect of the above matter.

G. P. KAPADIA & CO.
Chartered Accountants

7. We did not review the interim financial results of subsidiaries included in the consolidated unaudited financial results, whose interim financial results reflect unaudited total assets of Rs 882.51 lakhs and cash flows of Rs 272.32 lakhs as at 30th September 2024, unaudited total revenue from operations of Rs 88.15 lakhs for the period ended 30 September 2024 and profit from associates of Rs 3.86 lakhs, as considered in the consolidated unaudited financial results. These financial results have been prepared by the management and provided to us duly certified and our opinion on the consolidated unaudited financial results, in so far as it relates to the amounts and disclosures included in respect of those Subsidiary companies and associate is based solely on the financial result of the subsidiaries and associate as referred aforesaid. Our conclusion on the Statement is not modified in respect of the above matter.

For G.P Kapadia & Co.
(Chartered Accountants)
FRN No.: 104768W

Digitally signed by ATUL BABUBHAI DESAI
Date: 2024.11.11 13:40:46 +05'30'

Atul Desai
(Partner)
Membership No. 030850
Place: Mumbai
Date: 11th November 2024
UDIN: 24030850BKAWGN3517

**UTILIZATION OF ISSUE PROCEEDS CERTIFICATE
OF UNIHEALTH CONSULTANCY LIMITED**

To,

The Board of Directors,
Unihealth Consultancy Limited,
H-13/14 Everest, 156, Tardeo Road, Mumbai, Maharashtra 400034

Respected Sir/Madam,

Sub: Certificate pursuant to NSE circular No. NSE/CML/2024/23 dated September 05, 2024 for expenditure incurred in relation to the Initial offer proceeds of public issue for Unihealth Consultancy Limited ("the Company").

We have been requested to certify expenditure incurred by the Company in relation to the Initial Offer proceeds of Public Issue of the Company. Based on verification of relevant documents and details furnished by the management of the company, we hereby certify, the utilisation of Issue Proceeds of Initial Public offer of the company up to September 30, 2024, as mentioned below in the prescribed Annexure "A".

Annexure "A"

(Rs. In Lakhs)

Sr. No.	Object as disclosed in the Offer Document	Amount disclosed in the Offer Document	Actual Utilized Amount	Unutilized Amount	Remarks
1.	Investment in joint venture, Victoria Hospital Limited (VHL), Kampala, Uganda for funding its capital expenditure requirements for proposed expansion and working capital requirements of VHL	1700.00	1259.02	440.98	NIL

G. P. KAPADIA & CO.

Chartered Accountants

2.	Investment in joint venture, UMC Global Health Limited (UMCGHL), Nigeria for funding its capital expenditure requirements for proposed expansion	460.00	111.56	348.44	NIL
3.	Investment in subsidiary, Biohealth Limited (BL), Tanzania for funding its capital expenditure requirements for proposed expansion (Refer Note)	1587.50	608.65	978.85	NIL
4.	General Corporate Purpose	1093.08	1093.08	-	NIL
5.	Issue Expenses (Net off from Gross IPO Proceeds of Rs. 5654.88 Lakhs and Net IPO proceeds Rs. 4840.58 Lakhs as per offer document)	814.30	814.30	-	NIL
	Total	5654.88	3886.61	1768.27	

Note : The original object as disclosed in the offer document was further altered by passing a resolution to vary the utilisation of proceeds raised by the Company through an initial public offering of equity shares (the 'IPO') made in pursuance of the Prospectus dated September 14, 2023 (the 'Prospectus') and reallocate the unutilized proceeds for the objects as set out in the Postal Ballot Notice, have been passed with requisite majority on Wednesday, June 26, 2024. Out of initial proposed amount i.e. Rs. 1587.50 Lakhs, Rs.1350 Lakhs were reallocated for investing as equity and debt in UMC Hospitals Private Limited, a subsidiary of the Company in India and in Unihealth Holdings Limited, the wholly owned subsidiary of the Company in Mauritius, to support expansion and acquisition of projects across India and Africa, in furtherance of the current objects of the Company. The utilised amount disclosed in the above table is consolidated utilised amount after considering the object reallocation as mentioned .

For G.P Kapadia & Co.
(Chartered Accountants)
FRN No.: 104768W

Digitally signed by ATUL
BABUBHAI DESAI
Date: 2024.11.11 13:55:16 +05'30'

Atul Desai
(Partner)
Membership No. 030850
Place: Mumbai
Date: 11th November, 2024
UDIN: 24030850BKAWGO8670

Annexure A

STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE

Statement on deviation / variation in utilisation of funds raised

Name of listed entity	Unihealth Consultancy Limited
Mode of Fund Raising	Public Issues of Equity shares
Date of Raising Funds	September 15, 2023
Amount Raised	Rs. 56,54,88,000/-
Report filed for half year ended	September 30, 2024
Monitoring Agency	Not Applicable
Monitoring Agency Name, if applicable	Not Applicable
Is there a Deviation / Variation in use of funds raised	Yes
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Yes
If Yes, Date of shareholder Approval	June 26, 2024 (through postal ballot)
Explanation for the Deviation / Variation	Attached as 'Annexure C'
Comments of the Audit Committee after review	None
Comments of the auditors, if any	None



Objects for which funds have been raised and where there has been a deviation, in the following table

(Rs. In lakhs)

Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised	Amount of Deviation/ Variation for the half year ended 30.09.2024 according to applicable object	Remarks if any
Investment in our joint venture, Victoria Hospital Limited (VHL), Kampala, Uganda for funding its capital expenditure requirements for proposed expansion and working capital requirements of VHL	No Modification	1700.00	NA	1259.02	0	-
Investment in our joint venture, UMC Global Health Limited (UMCGHL), Nigeria for funding its capital expenditure requirements for proposed expansion	No Modification	460.00	NA	111.56	0	-
Investment in our subsidiary, Biohealth Limited (BL), Tanzania for funding its capital expenditure requirements for proposed expansion	As per the Prospectus, Rs. 1,587.50 lakhs was originally allocated to Biohealth Limited (BL), Tanzania for funding its capital expenditure. Out of this unutilized amount, Rs. 1,350 lakhs has now been reallocated to our subsidiaries, UMC Hospitals Private Limited (India) and Unihealth Holdings Limited (Mauritius) to support expansion and acquisition of projects across India and Africa	1587.50	237.50	169.60	(1350.00)	-



NA	Investment in our subsidiaries namely UMC Hospitals Private Limited (India) and in Unihealth Holdings Limited (Mauritius) to support expansion and acquisition of projects across India and Africa	NIL	1350	439.05	1350	Shareholders approved the said reallocation of unutilized proceeds of Rs. 1,350 lakhs for the modified objects by passing special resolution through Postal Ballot on June 26, 2024.
General Corporate Purpose	No Modification	1093.08	-	1093.08	0	-
Issue Expenses	No Modification	814.30	-	814.30	0	-

Deviation or variation could mean:

- (a) Deviation in the objects or purposes for which the funds have been raised or
- (b) Deviation in the amount of funds actually utilized as against what was originally disclosed or
- (c) Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter of offer, etc.

For Unihealth Consultancy Limited

Binita
Mayur
Patel

Digitally signed by
Binita Mayur Patel
Date: 2024.11.11
14:06:17 +05'30'

Binita Patel
Company Secretary & Compliance Officer



G. P. KAPADIA & CO.

Chartered Accountants

4th Floor, Hamam House, Ambalal Doshi Marg, Fort, Mumbai - 400 001

+ 91 22 2265 4239 / 4313 info.ho@gpkapadia.com www.gpkapadia.com



**UTILIZATION OF ISSUE PROCEEDS CERTIFICATE
OF UNIHEALTH CONSULTANCY LIMITED**

To,

The Board of Directors,
Unihealth Consultancy Limited,
H-13/14 Everest, 156, Tardeo Road, Mumbai, Maharashtra 400034

Respected Sir/Madam,

Sub: Certificate pursuant to NSE circular No. NSE/CML/2024/23 dated September 05, 2024 for expenditure incurred in relation to the Initial offer proceeds of public issue for Unihealth Consultancy Limited ("the Company").

We have been requested to certify expenditure incurred by the Company in relation to the Initial Offer proceeds of Public Issue of the Company. Based on verification of relevant documents and details furnished by the management of the company, we hereby certify, the utilisation of Issue Proceeds of Initial Public offer of the company up to September 30, 2024, as mentioned below in the prescribed Annexure "A".

Annexure "A"

(Rs. In Lakhs)

Sr. No.	Object as disclosed in the Offer Document	Amount disclosed in the Offer Document	Actual Utilized Amount	Unutilized Amount	Remarks
1.	Investment in joint venture, Victoria Hospital Limited (VHL), Kampala, Uganda for funding its capital expenditure requirements for proposed expansion and working capital requirements of VHL	1700.00	1259.02	440.98	NIL

G. P. KAPADIA & CO.

Chartered Accountants

2.	Investment in joint venture, UMC Global Health Limited (UMCGHL), Nigeria for funding its capital expenditure requirements for proposed expansion	460.00	111.56	348.44	NIL
3.	Investment in subsidiary, Biohealth Limited (BL), Tanzania for funding its capital expenditure requirements for proposed expansion (Refer Note)	1587.50	608.65	978.85	NIL
4.	General Corporate Purpose	1093.08	1093.08	-	NIL
5.	Issue Expenses (Net off from Gross IPO Proceeds of Rs. 5654.88 Lakhs and Net IPO proceeds Rs. 4840.58 Lakhs as per offer document)	814.30	814.30	-	NIL
	Total	5654.88	3886.61	1768.27	

Note : The original object as disclosed in the offer document was further altered by passing a resolution to vary the utilisation of proceeds raised by the Company through an initial public offering of equity shares (the 'IPO') made in pursuance of the Prospectus dated September 14, 2023 (the 'Prospectus') and reallocate the unutilized proceeds for the objects as set out in the Postal Ballot Notice, have been passed with requisite majority on Wednesday, June 26, 2024. Out of initial proposed amount i.e. Rs. 1587.50 Lakhs, Rs.1350 Lakhs were reallocated for investing as equity and debt in UMC Hospitals Private Limited, a subsidiary of the Company in India and in Unihealth Holdings Limited, the wholly owned subsidiary of the Company in Mauritius, to support expansion and acquisition of projects across India and Africa, in furtherance of the current objects of the Company. The utilised amount disclosed in the above table is consolidated utilised amount after considering the object reallocation as mentioned .

For G.P Kapadia & Co.
(Chartered Accountants)
FRN No.: 104768W

Digitally signed by ATUL
BABUBHAI DESAI
Date: 2024.11.11 13:55:16 +05'30'

Atul Desai
(Partner)
Membership No. 030850
Place: Mumbai
Date: 11th November, 2024
UDIN: 24030850BKA WGO8670

Annexure C

EXPLANATION FOR THE DEVIATION / VARIATION

The Company vide its Prospectus dated September 14, 2023 ("Prospectus") had raised Rs. 5654.88 lakhs from the initial public offer of its equity shares (the 'IPO'). The net proceeds from the IPO were Rs. 4840.58 lakhs /- (hereinafter referred to as "IPO Proceeds"). The Equity shares of the Company got listed on the SME Segment of National Stock Exchange of India Limited ("NSE") on September 21, 2023.

The Board of directors by a resolution dated 23rd May, 2024 passed at its meeting, proposed to vary the objects for utilisation of proceeds raised by the Company through the IPO and reallocate the unutilized proceeds, which was approved by the shareholders of the Company vide Special resolution passed through postal ballot on June 26, 2024.

The details of variation of objects and justification for the same is as under:

In line with the Company's vision of expanding its commissioned bed strength by setting up and/or acquiring tertiary care and/or multi-specialty and/or super-specialty hospitals in key high growth countries of Africa as well as in India, the Company has been exploring possible opportunities for probable acquisitions and collaborations.

Following comprehensive and detailed market assessment and study, the Company opined that investments in the Indian healthcare sector are likely to be of strategic benefit for the Company's growth plans on an immediate basis. In furtherance to the same, UMC Hospitals Private Limited had been incorporated by the Company as its subsidiary, to set up, acquire operations and enter into management contracts for tertiary care hospitals in India. The Company, via UMC Hospitals Private Limited, intends to add a capacity of 150 to 250 commissioned beds across one or more tertiary care hospitals in India under its operational management in the coming 24-36 months. In line with the Company's proposed plans to establish a pan-African presence and expand its existing bed capacity across Africa from 200 tertiary care beds to more than 500 commissioned beds in the coming 36 months, the Company had incorporated a wholly owned subsidiary, Unihealth Holdings Limited, in Mauritius. The said subsidiary intends to make investments to acquire as well as invest into setting up of facilities in line with the Company's vision and growth plans, in key target countries of Africa.

In furtherance of the same, the Company intends to invest Rs. 1350 lakhs of the unutilised issue proceeds as equity capital and debt into UMC Hospitals Private Limited (India) and Unihealth Holdings Limited (Mauritius), to provide these companies with the required funds for probable investments to acquire and/or invest into setting up of the intended facilities in India and across Africa, an initiative that has necessitated the Company to vary the utilisation of proceeds of the IPO and reallocate the unutilized proceeds.



The Board considers it prudent to re-classify and extend the unutilized amount towards investment in the Company's other subsidiaries to lead to optimum utilization of IPO proceeds and maximize the return on investment for members of the Company, ensuring future growth of the Company.

For Unihealth Consultancy Limited

Binita
Mayur
Patel

Digitally signed
by Binita Mayur
Patel
Date: 2024.11.11
14:06:49 +05'30'

Binita Patel
Company Secretary & Compliance Officer

